Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial

[1]  B. Di Camillo,et al.  Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice , 2020, Cardiovascular Diabetology.

[2]  S. Kuo,et al.  Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study , 2020, Cardiovascular Diabetology.

[3]  Lefeng Wang,et al.  Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis , 2020, Cardiovascular Diabetology.

[4]  Maurice B. Bizino,et al.  Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double‐Blind, Randomized, Placebo‐Controlled Trial , 2019, Journal of magnetic resonance imaging : JMRI.

[5]  Maurice B. Bizino,et al.  Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation , 2019, Diabetologia.

[6]  J. Hecksher-Sørensen,et al.  The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.

[7]  Maurice B. Bizino,et al.  High spatial resolution free-breathing 3D late gadolinium enhancement cardiac magnetic resonance imaging in ischaemic and non-ischaemic cardiomyopathy: quantitative assessment of scar mass and image quality , 2018, European Radiology.

[8]  C. Streutker,et al.  GLP-1 Receptor Expression Within the Human Heart , 2018, Endocrinology.

[9]  J. Lekakis,et al.  Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes , 2018, Cardiovascular Diabetology.

[10]  L. Bojö,et al.  Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study , 2017, Front. Endocrinol..

[11]  O. Belton,et al.  Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis , 2017, Cardiovascular Diabetology.

[12]  T. Hirano,et al.  The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis , 2017, Cardiovascular Diabetology.

[13]  D. Drucker,et al.  Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors , 2017, Circulation.

[14]  J. Jensen,et al.  Effect of exercise combined with glucagon‐like peptide‐1 receptor agonist treatment on cardiac function: A randomized double‐blind placebo‐controlled clinical trial , 2017, Diabetes, obesity & metabolism.

[15]  Stefan K. Piechnik,et al.  Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort , 2017, Journal of Cardiovascular Magnetic Resonance.

[16]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[17]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[18]  G. Adda,et al.  Improved diastolic function in type 2 diabetes after a six month liraglutide treatment. , 2016, Diabetes research and clinical practice.

[19]  John B Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[20]  J. Holst,et al.  Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial , 2016, Diabetes, obesity & metabolism.

[21]  Jia-Rong Wu,et al.  Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review , 2015, Heart Failure Reviews.

[22]  J. Francis,et al.  Effect of Selective Heart Rate Slowing in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[23]  C. Liang,et al.  Preclinical Systolic and Diastolic Dysfunctions in Metabolically Healthy and Unhealthy Obese Individuals , 2015, Circulation. Heart failure.

[24]  P. Reaven,et al.  Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans , 2015, Diabetes.

[25]  M. Pfeffer,et al.  Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. , 2014, The lancet. Diabetes & endocrinology.

[26]  L. de las Fuentes,et al.  Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. , 2014, Journal of the American College of Cardiology.

[27]  D. Drucker,et al.  Cardiovascular actions of incretin-based therapies. , 2014, Circulation research.

[28]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[29]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[30]  Shunichi Homma,et al.  Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. , 2011, Journal of the American College of Cardiology.

[31]  Jeroen J. Bax,et al.  Left ventricular diastolic function assessment from three‐dimensional three‐directional velocity‐encoded MRI with retrospective valve tracking , 2011, Journal of magnetic resonance imaging : JMRI.

[32]  J. Westenberg.  CMR for Assessment of Diastolic Function , 2011, Current cardiovascular imaging reports.

[33]  C. Scott,et al.  Changes in diastolic dysfunction in diabetes mellitus over time. , 2009, The American journal of cardiology.

[34]  Jeroen J. Bax,et al.  Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus , 2009, Circulation.

[35]  L. Rydén,et al.  A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study , 2009, European journal of heart failure.

[36]  Hanno Pijl,et al.  Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. , 2008, Journal of the American College of Cardiology.

[37]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[38]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[39]  Jeroen J. Bax,et al.  Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. , 2005, Journal of the American College of Cardiology.

[40]  B. Howard,et al.  Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. , 2003, Journal of the American College of Cardiology.

[41]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[42]  B V Howard,et al.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. , 2001, Journal of the American College of Cardiology.

[43]  M. Cerqueira,et al.  Influence of sympathetic stimulation and parasympathetic withdrawal on Doppler echocardiographic left ventricular diastolic filling velocities in young normal subjects. , 1991, The American journal of cardiology.